Heart failure is one of most prevalent diseases in the world and frequently results from sustained biomechanical overload [1] . After a prolonged period of compensatory adaptation of cardiac hypertrophy, the myocardium undergoes functional and histological deterioration [2, 3] . Increasing evidence suggests that mechanical left ventricular wall stress induces cardiac hypertrophy and failure, in part, by induction of reactive oxygen species (ROS) [4, 5] 
China. Pistils of saffron are always used in traditional Indian medicine as analgesics and cardioprotective agents. Crocetin is a kind of carotenoid present in saffron, and accumulating evidence demonstrated that it possesses a number of pharmacological activities
. Crocetin can show strong antioxidant effect including scavenging oxygen free radicals, suppressing lipid peroxidation, protecting myocardial cell and modulating intracellular Ca 2ϩ flux. Crocetin has also been reported to inhibit tumour cell proliferation, protect against hepatotoxicity, prevent atherosclerosis in hyperlipidaemic rabbits and improve insulin resistance in rats [19, 20] . Recently, Shen et al. [21, 22] 
USA). Transforming growth factor (TGF)-␤1 was purchased from R&D Systems (Minneapolis, MN, USA). Foetal calf serum (FCS) was obtained from Hyclone (Logan, UT, USA). NF-B-, connective tissue growth factor (CTGF)-and collagen 1A2 (COL1A2)-luc report constructs
were described previously [23] .
Crocetin was obtained from MP Biomedicals (Solon, OH, USA), and cell culture reagents and all other reagents were obtained from Sigma (Oakville, ON, Canada). Crocetin was dissolved in dimethylsulphoxide (DMSO) medium for all in vitro studies.

Cultured neonatal rat cardiac myocytes and fibroblasts
Primary cultures of cardiac myocytes were prepared as described previously [23, 24] . Cells from the hearts of 1-to 2-day-old Sprague-Dawley rats were seeded at a density of 1 ϫ 10 6 
/well into 6-well culture plates in a plating medium consisting of F10 medium supplemented with 10% FCS and penicillin/streptomycin. After 48 hrs, the culture medium was replaced with F10 medium containing 0.1% FCS and 5-Bromo-2Ј-deoxyuridine (BrdU) (100 M). After 24 hrs of serum starvation, crocetin alone or crocetin followed by Ang II (1M) was added to the medium and the cultures were incubated for the indicated time. Viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay.
Cultures of neonatal rat cardiac fibroblasts were described previously [23] . Briefly (Fig. 3C) (Fig. 3H) .
Results
Crocetin attenuates cardiac hypertrophy in vitro
Crocetin blunts inflammatory response induced by pressure overload
Increasing number of studies suggest that inflammation plays an important role in the development of cardiac and vascular diseases [25, 26] Fig. 4A and B) . (Fig. 4D) . (Fig. 5A) . To confirm that the observed effects of (Fig. 5D) . (Fig. 5E) . Interestingly, Ad-caERK1/2 infection obviously reversed the inhibitory effects of crocetin on collagen synthesis and COL1A2 promoter activity (Fig. 5E ). These findings suggest that crocetin blocks collagen synthesis by disrupting MEK-ERK1/ 2-dependent Smad2/3 signalling.
. To determine whether crocetin can suppress the inflammatory responses in the heart, we examined the expression of inflammatory mediators MCP-1, interleukin (IL)-1␤ and tumour necrosis factor (TNF)-␣ in cardiac tissue. Our results showed that crocetin significantly decreased the levels of monocyte chemoattractant protein 1 (MCP-1), IL-1␤ and TNF-␣ mRNA and protein expression compared with the vehicle-treated AB mice (
To evaluate the underlying mechanisms accounting for the potential aetiologies of the inhibitory effects of crocetin on inflammatory responses, we evaluated NF-B signalling in the mice. Treatment with crocetin abolished the increased activation of NF-B observed in the myocardium of the vehicle-treated mice 8 weeks after AB (Fig. 4C). To further determine the molecular mechanisms through
Fig. 2 Crocetin blunts cardiac hypertrophy in vivo. (A) Statistical results of HW/BW ratio, LW/BW ratio and myocyte cross-sectional areas (n ϭ 300 cells per section) at 8 weeks after AB surgery (n ϭ 8). (B) Echocardiography results from four groups of mice at 8 weeks after AB or sham surgery. (C)
(G) Crocetin inhibits pressure overload-induced GATA-4 DNA-binding activity. (H) Inhibition of ERK1/2 by treatment of U0126 (5 M) or infection with Ad-dnERK1/2-blocked GATA-4 activation induced by Ang II. which crocetin blocks NF-B activation in vivo, we analysed IB␣ phosphorylation and IKK activation processing. Heart lysates from samples obtained from mice 8 weeks after AB were prepared and Western blot analysis was performed. The detection of IB␣ phosphorylation and IB␣ degradation in the vehicle-treated AB mice was significantly impaired after treatment with crocetin
Because the phosphorylation of IB␣ is mediated by IKK␤, these findings suggested to us that crocetin might have an inhibitory role in IKK␤ activation. Indeed, we observed that the activation, but not the protein expression level, of IKK␤ was significantly attenuated by the administration of crocetin (Fig. 4E). Importantly, our further study demonstrated that NAC also blocked Ang IIinduced NF-B activation in cardiac myocytes (Fig. 4F). These results indicate that crocetin inhibits inflammation by blocking NF-B signalling in response to chronic pressure overload.
Crocetin inhibits collagen synthesis induced by Ang II in vitro
Fig. 4 Crocetin inhibits inflammation induced by pressure overload. (A, B) Real-time PCR and Western blot analysis of TNF-␣, IL-1␤ and MCP-1 mRNA and protein expression in the myocardium obtained from the indicated groups (n ϭ 6). (C) The DNA-binding activity of NF-B in the left ventricle of the indicated groups (n ϭ 5). (D) Western blot analysis of IB␣ degradation and IB␣ phosphorylation of the myocardium was obtained from the indicated animals at 8 weeks after AB (n ϭ 4). (E) IKK␤ activity was shown in the indicated group (n ϭ 4). Each
Crocetin almost completely suppressed Smad 2 phosphorylation as well as Smad 2/3 nuclear translocation but had negligible effects on Smad 2 protein expression (Fig. 5D). To further examine the mechanisms involved, we used confluent cardiac fibroblasts infected with Ad-GFP, Ad-caERK1/2 or Ad-dnERK1/2. Activation of ERK1/2 by infection with Ad-caERK1/2 revealed a significant increase in collagen synthesis and COL1A2 promoter activity in response to Ang II, whereas blocking ERK1/2 activity by Ad-dnERK1/2 infection almost completely abrogated them
Crocetin blocks fibrosis induced by pressure overload
To further confirm our in vitro findings, we examined the potential anti-fibrotic effect of crocetin in vivo. To determine the extent of fibrosis in the heart 8 weeks after AB, paraffin-embedded slides were stained with PSR and examined under a light microscope. In contrast to normal hearts with little fibrotic tissue, marked interstitial fibrosis was detected in the vehicle-treated AB mice. Crocetin treatment, however, significantly reduced the extent of cardiac fibrosis in vivo (Fig. 6A and B) . Subsequent analysis of mRNA expression levels of known mediators of fibrosis including TGF-␤1, collagen I and CTGF demonstrated a blunted response following crocetin administration compared with the vehicletreated group (Fig. 6B and C) . To further elucidate the cellular mechanisms underlying the anti-fibrotic effects of crocetin, we assessed its regulatory role in Smad cascade activation. Upon analysis of the crocetin-treated group, we observed suppressed Smad-2 phosphorylation and Smad 2/3 nuclear translocation in mice (Fig. 6D) . Fig. 7A and B) . Interestingly, crocetin treatment starting after the initial 2 weeks of AB for a period of 6 weeks was able to reverse the remodelling, contractile dysfunction and cardiac ANP, BNP and Myh7 mRNA expression levels towards normal control values, ultimately preventing the transition to heart failure ( Fig. 7A-D) .
Crocetin ameliorates established cardiac hypertrophy in vivo
Discussion
The results from our study demonstrate that crocetin protects against cardiac hypertrophy both in vitro and in vivo. The protective role of crocetin in cardiac hypertrophy is mediated by direct interruption of ROS-dependent MEK-ERK1/2 signalling. This results in the protection of the host from the combined deleterious effects of cardiac hypertrophy, inflammation and fibrosis (Fig. 8) Crocetin is one of about 600 naturally occurring carotenoids and exists mainly in the stigma of saffron and the fruit of Cardenia jasminoides [27] . Recent studies provide additional evidence that crocetin could also exert protective effects against the cardiovascular system, including blocking excessive proliferation of vascular smooth cells [28] , lowering serum cholesterol levels, increasing high-density lipoprotein and reducing evolving atherosclerosis [29] [30, 31] . Nakamura et al. [32] in oxidative stress. The differences in antioxidant reserve among experimental modes may explain the discrepancy regarding the effect of antioxidants on cardiac hypertrophy. These findings suggest that both ROS-dependent and -independent signalling pathways are present in the signal transduction system in cardiac hypertrophy [11] . Although 
